Changes in quality of life during palliative chemotherapy for solid cancer
- 28 January 2005
- journal article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 13 (7) , 515-521
- https://doi.org/10.1007/s00520-004-0708-0
Abstract
We conducted this prospective study to assess the changes in quality of life (QOL), anxiety and depression in patients receiving palliative chemotherapy for solid cancers.Patients were eligible if they had histologically confirmed metastatic or recurrent cancer and a life expectancy of more than 6 months, and were able to complete the self-administered questionnaires. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) and Hospital Anxiety and Depression Scale (HADS) were used to measure the effects of chemotherapy on the patients' QOL, anxiety and depression at baseline and three times after every three cycles of chemotherapy.From July 2001 to October 2003, 146 patients were recruited, and of these 98 completed the questionnaires and 48 were withdrawn from the trial (27 lost to follow-up, 11 withdrew consent, 5 for toxicity, 5 for progression of the cancer). Their median age was 58 years (range 28-78 years) and the male to female ratio was 1.6. Of the 146 patients, 52 had gastric cancer, 39 non-small-cell cancer, 29 colorectal cancer, 11 breast cancer, and 15 had other cancers. Initial QOL scores were closely related to performance status. Compared with baseline, clinically meaningful relief (score decreased by more than 10) of symptoms such as pain and sleep disturbance was observed. There was significant improvement (score increased by more than 10) in the functional scales after the first cycle of chemotherapy, but these effects did not persist throughout the whole course of therapy. The incidences of probable anxiety and depression disorder before chemotherapy were 20% and 29%, respectively. The anxiety scores decreased throughout the period of intervention. Pretreatment anxiety and depression were negatively correlated with baseline QOL scores.Palliative chemotherapy treatment in patients with solid cancer improved cancer-related symptoms, lessened anxiety and did not disturb the QOL of cancer patients.Keywords
This publication has 11 references indexed in Scilit:
- Validation of the Korean version of the EORTC QLQ-C30Quality of Life Research, 2004
- Measuring Quality of Life in Routine Oncology Practice Improves Communication and Patient Well-Being: A Randomized Controlled TrialJournal of Clinical Oncology, 2004
- Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Anxiety Disorders in Cancer Patients: Their Nature, Associations, and Relation to Quality of LifeJournal of Clinical Oncology, 2002
- Unsolved problems in evaluating the quality of life of cancer patientsAnnals of Oncology, 2001
- Anxiety and depression in cancer patients: relation between the Hospital Anxiety and Depression Scale and the European Organization for Research and Treatment of Cancer Core Quality of Life QuestionnaireJournal of Psychosomatic Research, 2000
- Interpreting the significance of changes in health-related quality-of-life scores.Journal of Clinical Oncology, 1998
- The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30Quality of Life Research, 1996
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983